Drug Trial Radar · NCT02960763
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
742
Actual
Start
Feb 24, 2017
Primary completion
Sep 28, 2020
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; National Institute of Mental Health (NIMH)
- First posted
- Nov 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
Conditions
- Treatment Resistant Depression
- Major Depressive Disorder
- Treatment-Refractory Depression
- Late Life Depression
- Geriatric Depression
Interventions
Aripiprazole AugmentationDrug
Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
Bupropion AugmentationDrug
Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Switch to bupropionDrug
Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Lithium AugmentationDrug
Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Switch to nortriptylineDrug
Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- Psychological Well-BeingTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
- Number of Participants With Remission From DepressionTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
- Serious Adverse EventsTime frame: Step 1 (10 weeks), Step 2 (10 weeks), a period of up to 20 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
UCLA Late-Life Mood, Stress, and Wellness Research Program
Los Angeles, California
Washington University School of Medicine Healthy Mind Lab
St Louis, Missouri
Columbia University Adult and Late Life Depression Clinic
New York, New York
UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program
Pittsburgh, Pennsylvania
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.